Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q2 2022 Earnings Presentation

40 slides from Neurocrine Biosciences's earnings presentation, Aug 4, 2022

  1. Slide 1: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q2 2022 Corporate Presentation August 4, 2022 Nasdaq: NBIX

  2. Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures

    Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our

  3. Slide 3: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth * Raised 2022 Annual ~500,000 undiagnosed and untreated patients with Sales Guidance to Tardive Dyskinesia (TD) in the U.S. $1.35B to $1.4B Significant Opportunity for Growth R&D Focus Robust 12 Programs Currently in Mid-to-Late-Stage Studies • Neurol

  4. Slide 4: Q2 2022 Highlights and Future Key Milestones & Activities

    Q2 2022 Highlights and Future Key Milestones & Activities Q2 2022 Highlights Future Key Milestones & Activities ▪ INGREZZA® (valbenazine) Net Product Sales of ~$350 Million ▪ FY 2022 INGREZZA Guidance Raised to $1.35 Billion to $1.40 Billion − Q2 2022 INGREZZA Net Sales and TRx Grew 32% and 31%, ▪ s

  5. Slide 5: Strong Pipeline Momentum

    Strong Pipeline Momentum Phase 1 Phase 2 Phase 3 Partner Upcoming Milestones Neurology Supplemental New Drug Application (sNDA) valbenazine* Chorea in Huntington Disease Filing in 2H 2022 valbenazine* Dyskinetic Cerebral Palsy Registrational Top-Line Data Expected in 2024 NBI-827104 Rare Pediatric E

  6. Slide 6: Pipeline Features Novel Mechanisms to Treat Intractable Diseases

    Pipeline Features Novel Mechanisms to Treat Intractable Diseases Focused on Neurology, Neuroendocrinology, and Neuropsychiatry Neurology Neuroendocrinology Epileptic SCN8A Encephalopathy Tardive Focal Onset Developmental Uterine Congenital with Continuous Endometriosis Dyskinesia Seizures (FOS) and

  7. Slide 7: Significant Clinical Progress Expected Through 2023

    Significant Clinical Progress Expected Through 2023 Significant Milestones in 2H 2022 2023 Clinical Activities & Milestones NBI-827104 in EE-CSWS Crinecerfont for CAH in Adults Phase 2 Data Registrational Top-line Data Valbenazine in Chorea in Huntington Disease Crinecerfont for CAH in Children & Ad

  8. Slide 8: Q2 2022 Financial Summary

    Q2 2022 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q2 2022 Q2 2021 Highlights / Comments Revenue $378 $289 Q2 2022 INGREZZA Sales of $350M with Record - Product Sales, Net 352 267 New Patients and Continued Strong Compliance / Persistence Rates for Existing Patients - Coll

  9. Slide 9: 2022 INGREZZA Sales and Operating Expense Guidance

    2022 INGREZZA Sales and Operating Expense Guidance 2021 2022 Previous 2022 Current Item ($ Millions) Comments Actuals Guidance Range Guidance Range INGREZZA Net Product Sales1 $1,082 $1,250 - $1,350 $1,350 - $1,400 Raising Range GAAP R&D Expense2 $328 $380 - $415 $415 - $450 Updating R&D GAAP and No

  10. Slide 10: Corporate Sustainability

    Corporate Sustainability Our Purpose: Relieve Suffering for People with Great Needs, but Few Options Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safety standards Comprehensive Quality Industry-leading employee Improving profit

  11. Slide 11: Our Medicines, Our Patients

    © NEYROCRINE Our Medicines, Our Patients

  12. Slide 12: INGREZZA Quarterly Net Sales Performance

    INGREZZA Quarterly Net Sales Performance ($MM) $360 $350 $340 5th Sequential Period of Growth $320 $301 $303 $300 $287 $280 $265 $260 $254 $240 $240 $230 $220 $200 Q3 '20 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 12

  13. Slide 13: Substantial Impact on TD Patients and Care Partners

    Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo

  14. Slide 14: Nascent TD Market Presents Significant Opportunity

    Nascent TD Market Presents Significant Opportunity Only ~25% of TD Patients Diagnosed E S T I M AT E D T O A F F E C T ~600,000 ✓ Patients with TD diagnosed ✓ Only half of diagnosed patients receive treatment with VMAT2 inhibitor like INGREZZA people in the U.S. Diagnosed Increasing Antipsychotic Pr

  15. Slide 15: Driving Long-Term Growth for INGREZZA

    Driving Long-Term Growth for INGREZZA Salesforce and distribution expansion INGREZZA and ONGENTYS offering greater access to neurology practices Investing in telemedicine capabilities Recommends patients with TD associated with antipsychotic therapy be treated with a VMAT2 inhibitor Patient outreach

  16. Slide 16: Filing sNDA for Valbenazine for Chorea in Huntington Disease in 2H 2022

    Filing Supplemental New Drug Application for Valbenazine for the Treatment of Chorea in Huntington Disease in 2H 2022 Valbenazine* Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia

  17. Slide 17: Valbenazine: Registrational Programs in ATS and DCP

    Valbenazine*: Registrational Programs in ATS and DCP Adjunctive Treatment of Schizophrenia (ATS) Dyskinetic Cerebral Palsy (DCP) Schizophrenia is one of the leading causes A form of cerebral palsy (CP) that affects of disability worldwide, affecting up to 3.5M ~15% of the approximately 500,000 to 1M

  18. Slide 18: ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor for Parkinson's Disease

    ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor for Parkinson’s Disease Provides Significant Reduction of Daily “Off” Time; Increase in Good “On” Time • Add-on treatment to levodopa/carbidopa prolongs clinical effects • One capsule, once a day treatment • Helps patients achieve m

  19. Slide 19: Neurology Pipeline

    © NEVROCRINE Neurology Pipeline

  20. Slide 20: Potential First-in-Class Neurology Programs

    Potential First-in-Class Neurology Programs Collaborations with Idorsia and Xenon Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies NBI-827104* Rare Pediatric Epilepsy: EE-CSWS Top-line Data Expected in 2H 2022 Focal Onset Seizures in Adults Top-line Data Expected in

  21. Slide 21: NBI-827104: Selective Cav Blocker

    NBI-827104*: Selective Cav Blocker NBI-827104 Investigational, potent, selective, orally active and brain penetrating T-type calcium channel blocker (Cav 3.1, Cav 3.2, Cav 3.3) with 1x/day dosing Program has potential to address other central nervous system diseases EE-CSWS Background EE-CSWS Progra

  22. Slide 22: NBI-921352: Selective Nav1.6 Inhibitor in Ongoing Phase 2 Studies

    NBI-921352*: Selective Nav 1.6 Inhibitor in Ongoing Phase 2 Studies Adult Focal Onset Seizures Background SCN8A-DEE Background Also referred to as partial-onset seizures, Rare pediatric epilepsy with occurrence of these are the most common form of seizures seizures beginning in the first 18 months o

  23. Slide 23: Neuroendocrinology Pipeline

    Neuroendocrinology Pipeline

  24. Slide 24: Classic Congenital Adrenal Hyperplasia (CAH)

    Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder Enzyme deficiency & reduced cortisol levels and excess androgen levels U.S. ~30,000* Europe ~50,000* Complex and Treatment Options Highly Stagnant for 60 Years Variable • Hormone replacement Symptoms • Do not address underlying issue

  25. Slide 25: Congenital Adrenal Hyperplasia Disease Mechanism

    Congenital Adrenal Hyperplasia Disease Mechanism Normal Homeostasis CAH Patients 25

  26. Slide 26: Crinecerfont Potentially Meets Challenges of the Standard of Care

    Crinecerfont* Potentially Meets Challenges of the Standard of Care Overtreatment Hypercortisolism Overtreatment Insulin Resistance Undertreatment Hypercortisolism Central Obesity Hyperandrogenism Osteoporosis Potentially Fatal Adrenal Crisis Insulin Resistance Impaired Glucose Tolerance CRINECERFONT

  27. Slide 27: Potential Paradigm Shift in the Treatment of CAH

    Potential Paradigm Shift in the Treatment of CAH Crinecerfont* Phase 3 Global Adult Registrational Study Ongoing Top-Line Results Phase 3 Global Pediatric Registrational Study Ongoing Expected in 2023 Potent Orally Active Selective Well-Tolerated *Crinecerfont is investigational and not approved in

  28. Slide 28: Neuropsychiatry Pipeline

    (5) NEUROCRINE BIOSCIENCES

  29. Slide 29: Potential First-in-Class Neuropsychiatry Programs

    Potential First-in-Class Neuropsychiatry Programs Takeda Collaborations Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies Cognitive Impairment Associated Luvadaxistat* Ongoing Phase 2 Study with Schizophrenia (CIAS) Inadequate Response to Treatment in NBI-1065845** Ma

  30. Slide 30: Luvadaxistat: D-Amino Acid Oxidase (DAAO) Inhibitor

    Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor • Once daily million people in the U.S. diagnosed • No titration requirement with schizophrenia Hypofu

  31. Slide 31: NBI-1065845: AMPA Potentiator

    NBI-1065845*: AMPA Potentiator Inadequate Response to Treatment NBI-1065845 in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in the • Once daily U.S. who live with MDD do not respond • Potential adjunctive treatment to available antidepressants

  32. Slide 32: NBI-1065846: GPR139 Agonist

    NBI-1065846*: GPR139 Agonist Anhedonia in Major Depressive Disorder NBI-1065846 260 million+ people worldwide are Potent first-in-class investigational GPR139 agonist • Once weekly affected by major depressive disorder • Potential adjunctive treatment (MDD). GPR139 is an orphan receptor in the haben

  33. Slide 33: Novel Muscarinic Receptor Agonists Collaboration with Sosei Heptares

    Novel Muscarinic Receptor Agonists Collaboration with Sosei Heptares Neurocrine Biosciences Initiating Clinical Studies for Muscarinic Portfolio Initiating clinical studies, including: ➢ Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 orthosteric agonist, as a potential treatment fo

  34. Slide 34: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth * Raised 2022 Annual ~500,000 undiagnosed and untreated patients with Sales Guidance to Tardive Dyskinesia (TD) in the U.S. $1.35B to $1.4B Significant Opportunity for Growth R&D Focus Robust 12 Programs Currently in Mid-to-Late-Stage Studies • Neurol

  35. Slide 35: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations neurocrine.com

  36. Slide 36: Condensed Consolidated Statements of Operations

    NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS: (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions, except per share data) 2022 2021 2022 2021 Revenues: Product sales, net $ 352.0 $ 266.8 $ 657.0 $ 497.8 Collaboration revenue 26.2 22.1 318 27

  37. Slide 37: Condensed Consolidated Balance Sheets

    NEUROCRINE BIOSCIENCES CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) NEUROCRINE BIOSCIENCES, INC. (unaudited) Cash, cash equivalents and debt securities available-for-sale Other current assets Total current assets Deferred tax assets Debt securities available-for-sale Right-of-use assets Equit

  38. Slide 38: Reconciliation of GAAP to Non-GAAP Financial Results

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) Three Months Ended Six Months Ended Tune 30, June 30, (in millions, except per share data) 2022 2021 2022 2021 GAAP net (loss) income $ (16.9) $ 423 $ G.0) $ 744 Adjustments Stock-bas

  39. Slide 39: Reconciliation of GAAP to Non-GAAP Expenses

    NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions) 2022 2021 2022 2021 GAAP R&D $ 135.9 $ 48 $ 238.1 $ 148.0 Adjustments: Stock-based compensation expense 16.2 92 28.7 24.2 Non-GAAP R&D $ 119.7 $ 65

  40. Slide 40: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q2 2022 Corporate Presentation August 4, 2022 Nasdaq: NBIX

Neurocrine Biosciences — Q2 2022 Earnings Presentation on 6ix